As of June 18, 2026, the three largest insider holders of VYGR are Biosciences Inc Neurocrine (TenPercentOwner, 8.58Mn shares), Capital, Llc Ecor1 (TenPercentOwner, 3.85Mn shares), Rock Ventures Iii, L.P. Third (TenPercentOwner, 3.19Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Biosciences Inc Neurocrine | - | 8,575,316 | 0 | 24 Feb, 2022 |
| Glenn Pierce | Interim Cso | 16,788 | 0 | 18 Jul, 2022 |
| Michael J Higgins | Interim President Ceo | 31,314 | 0 | 18 Jul, 2022 |
| Rock Ventures Iii, L.P. Third | - | 3,185,291 | 0 | 06 Feb, 2023 |
| Alfred Sandrock | President And Ceo | 472,549 | 0 | 03 Apr, 2026 |
| Robert W. Hesslein | Senior Vp General Counsel | 102,200 | 0 | 22 Mar, 2023 |
| Peter P. Pfreundschuh | Chief Financial Officer | 175,669 | 0 | 22 Feb, 2024 |
| Capital, Llc Ecor1 | - | 0 | 3,851,507 | 11 Jan, 2023 |
| Nathan D. Jorgensen | Chief Financial Officer | 151,416 | 0 | 26 Feb, 2026 |
| Julie Burek | Vp, Finance | 52,458 | 0 | 23 Mar, 2022 |
| Robin Swartz | Coo Cbo | 199,738 | 0 | 26 Feb, 2026 |
| Todd Alfred Carter | Chief Scientific Officer | 145,718 | 0 | 26 Feb, 2026 |
| Sandell Jacquelyn Fahey | Chief Legal Officer | 123,143 | 0 | 24 Feb, 2025 |
| Toby Ferguson | Chief Medical Officer | 183,914 | 0 | 10 Feb, 2026 |
| Gregory L. Shiferman | Svp And General Counsel | 50,000 | 0 | 03 Apr, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 01 Apr, 2026 | Gregory L. Shiferman | Common Stock | A | 50,000 | $0.00 | 50,000 | D | A |
| 02 Apr, 2026 | Alfred Sandrock | Common Stock | D | 11,511 | $3.87 | 472,549 | D | S |
| 24 Feb, 2026 | Alfred Sandrock | Common Stock | D | 14,197 | $3.79 | 484,060 | D | S |
| 24 Feb, 2026 | Todd Alfred Carter | Common Stock | D | 4,174 | $3.76 | 145,718 | D | S |
| 24 Feb, 2026 | Robin Swartz | Common Stock | D | 6,458 | $3.77 | 199,738 | D | S |
| 24 Feb, 2026 | Nathan D. Jorgensen | Common Stock | D | 4,668 | $3.77 | 151,416 | D | S |
| 18 Feb, 2026 | Todd Alfred Carter | Common Stock | D | 3,301 | $3.44 | 149,892 | D | S |
| 18 Feb, 2026 | Robin Swartz | Common Stock | D | 3,882 | $3.44 | 206,196 | D | S |
| 18 Feb, 2026 | Alfred Sandrock | Common Stock | D | 11,732 | $3.41 | 498,257 | D | S |
| 10 Feb, 2026 | Robin Swartz | Common Stock | D | 4,569 | $3.85 | 210,078 | D | S |
| 10 Feb, 2026 | Alfred Sandrock | Common Stock | D | 12,192 | $3.78 | 509,989 | D | S |
| 10 Feb, 2026 | Todd Alfred Carter | Common Stock | D | 3,525 | $3.85 | 153,193 | D | S |
| 06 Feb, 2026 | Alfred Sandrock | Common Stock | A | 86,250 | $0.00 | 522,181 | D | A |
| 06 Feb, 2026 | Robin Swartz | Common Stock | A | 45,000 | $0.00 | 214,647 | D | A |
| 06 Feb, 2026 | Todd Alfred Carter | Common Stock | A | 33,000 | $0.00 | 156,718 | D | A |
| 06 Feb, 2026 | Nathan D. Jorgensen | Common Stock | A | 32,250 | $0.00 | 156,084 | D | A |
| 06 Feb, 2026 | Toby Ferguson | Common Stock | A | 45,000 | $0.00 | 183,914 | D | A |
| 06 Feb, 2026 | Robin Swartz | Stock Option (Right to Buy) | A | 210,000 | $0.00 | 210,000 | D | A |
| 06 Feb, 2026 | Alfred Sandrock | Stock Option (Right to Buy) | A | 402,500 | $0.00 | 402,500 | D | A |
| 06 Feb, 2026 | Nathan D. Jorgensen | Stock Option (Right to Buy) | A | 150,500 | $0.00 | 150,500 | D | A |